Description
Mécanisme d’action
, RET RET CCDC6-RET RET V804L RET V804M RET M918T , IC50 0.5 nM , , DDR1 TRKC FLT3 JAK1-2 TRKA VEGFR2 PDGFRB FGFR1 , RET VEGFR2 FGFR2 JAK2 14 40 12 RET ,
Pharmacologie
12.1 Mecanisme d action , RET RET CCDC6-RET RET V804L RET V804M RET M918T , IC50 0.5 nM , Cmax , DDR1 TRKC FLT3 JAK1-2 TRKA VEGFR2 PDGFRB FGFR1 , RET VEGFR2 FGFR2 JAK2 14 40 12 RET
Posologie
2.1 RET GAVRETO [ (14)] FDA RET , GAVRETO 400 mg, GAVRETO 2 1 [ (12.3)]
Precautions
5.1 / GAVRETO (ILD) / GAVRETO ,12% , 3.3% 3-4 ,0.2% ILD / , GAVRETO ILD ILD , GAVRETO [ Posologie (2.3)]
Interactions médicamenteuses
7.1 GAVRETO CYP3A / P-gp CYP3A / P-gp [ (12.3)], GAVRETO GAVRETO CYP3A / P-gp , GAVRETO [ Posologie (2.4)] CYP3A CYP3A [ (12.3)], GAVRETO
Effets indésirables
Description / [ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] [ Precautions(5.4)] [ Precautions(5.5)] [ Precautions(5.6)] - [ Precautions(5.7)] 6.1 ,
Conservation
GAVRETO 100 , , , , HPMC , “BLU-667”, “100 ”, 60 NDC 50242-210-60 90 NDC 50242-210-90 120 NDC 50242-210-12





